公开(公告)号：EP4093406A1

公开(公告)日：2022-11-30

申请号：EP21744533.7

申请日：2021-01-22

申请人： Taiho Pharmaceutical Co., Ltd. ,  Otsuka Pharmaceutical Co., Ltd.

发明人： HOSHINO, Takuya ,  KOMIYA, Yu ,  NAKATSURU, Yoko ,  WALLIS, Nicola Gail

IPC分类号： A61K31/519 ,  A61K31/506 ,  A61K39/395 ,  A61K45/00 ,  A61P35/00

公开(公告)号：EP3718545A1

公开(公告)日：2020-10-07

申请号：EP18883950.0

申请日：2018-11-28

申请人： Taiho Pharmaceutical Co., Ltd.

发明人： UENO, Hiroyuki ,  HOSHINO, Takuya

IPC分类号： A61K31/4245 ,  A61K45/00 ,  A61P35/00 ,  A61P43/00 ,  C07D249/04

摘要： The present invention provides a method of enhancing an antitumor effect by a compound strongly inhibiting ribonucleotide reductase (RNR) or a salt thereof.
A combination formulation involving combined administration of a sulfonamide compound represented by Formula (I) [In the formula, X 1 represents an oxygen atom or the like; X 2 represents an oxygen atom; X 3 represents -NH-; X 4 represents a hydrogen atom or the like; R 1 represents -C(R 11 ) (R 12 )- or the like; R 11 and R 12 are the same or different and each represents a hydrogen atom or the like; R 2 represents an optionally substituted C6-C14 aromatic hydrocarbon group or the like; R 3 represents an optionally substituted C6-C14 aromatic hydrocarbon group or the like; R 4 represents a hydrogen atom or the like] or a salt thereof, having RNR inhibitory activity, and other antitumor agent(s).